RxDoctor Payments Data

Marieliz Alvarado Davila, MD

Pulmonary Disease · San Juan, PRNPI 1730129008

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by GSK at 26.4% of the total.

$5,886in general payments, 2019–2025

Across 112 payments — averaging $52.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$460
  • Genentech USA, Inc.$363
  • Merck$346
  • E.r. Squibb & Sons, L.L.C.$310
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,875100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,886 in reported general payments places this provider in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$23,214
Medicare patients
68
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter401$269,202
OfevNintedanib Esylate13$167,905
Breo ElliptaFluticasone/Vilanterol227$94,127
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate122$29,933
Wixela InhubFluticasone Propion/Salmeterol201$29,896
SymbicortBudesonide/Formoterol Fumarate94$22,450
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$16,259
Spiriva RespimatTiotropium Bromide29$15,484
EliquisApixaban18$12,477
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,516
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,739
Albuterol Sulfate HfaAlbuterol Sulfate227$9,020
Fluticasone Propionate463$7,911
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$5,439
Montelukast Sodium463$4,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,553$378,268670 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$460$199,64873 claims
AstraZenecaSymbicort, Breztri Aerosphere$1,335$32,189109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →